WHO News

Pandemic flu — communicating the risks

Dr Margaret Chan is from China. She obtained her MD degree from the University of Western Ontario, Canada, in 1977, and joined the Hong Kong Department of Health in 1978, where she began her career in public health. She was appointed Director of Health of Hong Kong in June 1994. After two decades of working closely with WHO, Chan joined the organization as Director of the Department of Protection of the Human Environment in 2003. In June 2005, she became Assistant Director-General for the Communicable Diseases cluster of departments and took up the newly-created post of Representative of the Director-General for Pandemic Influenza.

No public health issue has caught the public imagination over the last year as vividly as avian flu. Governments are scrambling to be prepared for a human flu pandemic that could kill millions of people. But public misconceptions abound about the nature of the threat to human health and how to respond to it. WHO hosted a meeting of public health experts in Geneva on 6–8 December to discuss how governments should communicate the risks posed by avian flu and the threat of a human flu pandemic to members of the public.

Q: WHO has convened a series of meetings over the last few months on avian influenza and the threat of a human influenza pandemic. Was it necessary to hold “yet another” meeting?
A: The December meeting was the first WHO meeting that focused exclusively on pandemic communications. It was the first step in building a global communication infrastructure to respond to the myriad challenges posed by a human influenza pandemic.

Q: Health ministries in many countries are concerned that they may be communicating uncertainty to the public when it comes to public information on avian influenza and human pandemic influenza? What is WHO advising them to do?
A: In accordance with WHO Outbreak Communication guidelines, WHO advises Member States to be as open and transparent as possible in their public communications regarding disease threats, including avian and pandemic influenza. Unfortunately, there is considerable uncertainty simply because there are many unknowns about the next influenza pandemic. There is no way for anyone to accurately predict things like when the next pandemic might strike, or how many people might be killed. While WHO recognizes that talking openly about a pandemic threat may raise concerns worldwide, we would not be fulfilling our public health mandate if we did not warn the world of this evolving threat.

Q: Can Member States take a one-size-fits-all approach to communicating these risks? Or do public information campaigns need to be tailored to cultural and other specifics? How can WHO help to develop such information campaigns?
A: These are some of the issues that were addressed at the 6–8 December meeting. Once working groups are established to move ahead on such issues, we will have some communications guidance available [for governments]. WHO will provide technical and communications advice regarding public information campaigns specifically on avian and pandemic influenza.

Q: How can governments justify to the public the WHO recommendation that individuals should not stockpile the antiviral drug, Tamiflu (oseltamivir), and in the event of a human influenza pandemic, how can governments justify selecting those who receive doses and those who do not? If governments get this message across in advance, will they not be more likely to have public cooperation and success in the event of a pandemic?
A: WHO does not recommend that individuals stockpile oseltamivir because this is a drug whose consumption requires medical supervision. National stockpiles of oseltamivir, like WHO stockpiles of oseltamivir, have a very specific public health purpose — to contain the emergence of a new pandemic strain, if possible, and to lessen the burden of death and disease. Widespread personal use of oseltamivir could provoke the emergence of a resistant strain, which then might have serious public health implications. There is still much uncertainty regarding the potential efficacy of oseltamivir in the next pandemic. No one knows if it will be effective against the pandemic strain and it should not be regarded as a silver bullet. National authorities will have to decide which populations will be eligible to receive it according to their own criteria.

“Investing in pandemic preparedness is essentially like investing in an insurance policy.”
**WHO clinical trials initiative to protect the public**

In response to calls for new standards and rules for the registration of studies involving humans participants, WHO is developing a common set of rules for registering clinical trials.

WHO plans to launch a global network of clinical trial registers in May 2006, the first step towards establishing a web-based search platform where members of the public can obtain full and detailed information about clinical trials. Currently, there are at least 50 registers of clinical trials around the world. The WHO International Clinical Trials Registry Platform is a major initiative to bring these registers together in a global network to provide a single point of access to the information stored in them.

The goal is to increase transparency and accountability on the part of companies and institutions that do clinical research, and, in turn, boost public trust and confidence in that research. "Registration of trials promotes scientific and ethical integrity and makes research more honest. When the system is up and running there will be no hiding of results," said Dr Patrick Unterlerchner, WHO Health Systems Analyst and Assistant to the Coordinator of the project.

The initiative comes in the wake of several cases of companies withholding negative research findings that sparked public outrage. Merck of the United States withdrew Vioxx from the market in 2004 after the drug was linked to an increased risk of heart attack and stroke, and in 2003, GlaxoSmithKline of the United Kingdom warned that the antidepressant, Paxil, should not be prescribed to minors as it could increase the risk of suicide.

In response, the International Committee of Medical Journal Editors (ICMJE), representing the world’s leading medical journals, agreed not to publish the results of any clinical trial unless that trial had been registered in a public register before the enrolment of the first patient.